Iza-bren met both dual primary endpoints, delivering statistically significant and clinically meaningful improvements in progression-free survival
The construction projects, which have already begun, will be finalised gradually from the end of 2027 through 202
Emcure to distribute Roche's kidney transplant and anemia drugs in India
KEYTRUDA had previously met its primary endpoint of progression-free survival in all patients
The TacroType test provides actionable genetic insights to help clinicians understand how individual patients metabolize tacrolimus
Zongertinib is setting a new standard as the first targeted therapy for treatment naïve patients with HER2-mutant advanced non-small cell lung cancer with demonstrated efficacy
The EIR was issued following an inspection of the facility from November 10 to November 21, 2025
Zydus has in-licensed FYB206, a proposed biosimilar to immuno-oncology therapy Keytruda (pembrolizumab), exclusively from Formycon AG for the U.S. and Canadian markets
The product addresses a market with approximately $66.8 million in annual sales as of December 2025.
Vinita has made expansion in the U.S. a core pillar of Lupin’s worldwide growth strategy
Subscribe To Our Newsletter & Stay Updated
